SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (10117)3/25/2009 11:33:39 PM
From: DewDiligence_on_SI  Read Replies (2) of 10345
 
BIIB’s claim of a lower-than-expected rate of PML in recently treated patients is somewhat disingenuous, IMO, because the comparison is apples vs oranges. The newly cited rate of 1 in 4,000 is for the initial 12 months of treatment, while the 1-in-935 rate in Tysabri’s FDA label is for a 28-month median duration.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News